Achieve Life Sciences (ACHV) Expected to Release Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Achieve Life Sciences to post earnings of ($0.20) per share and revenue of $10.65 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

Achieve Life Sciences (NASDAQ:ACHV) last released its earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.64). On average, analysts expect Achieve Life Sciences to post ($0.92) EPS for the current fiscal year and ($0.57) EPS for the next fiscal year.

Achieve Life Sciences Trading Up 1.8%

NASDAQ ACHV opened at $6.73 on Wednesday. The firm has a market capitalization of $692.52 million, a PE ratio of -4.34 and a beta of 2.42. The stock’s 50 day moving average is $7.40 and its 200 day moving average is $5.66. Achieve Life Sciences has a twelve month low of $2.62 and a twelve month high of $8.64. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.87.

Insider Buying and Selling at Achieve Life Sciences

In related news, Director Richard Stewart sold 20,626 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $8.49, for a total transaction of $175,114.74. Following the completion of the transaction, the director owned 208,249 shares of the company’s stock, valued at $1,768,034.01. This trade represents a 9.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.80% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have commented on ACHV shares. UBS Group reissued a “buy” rating on shares of Achieve Life Sciences in a research report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Wednesday, August 19th. Stifel Nicolaus set a $18.00 target price on shares of Achieve Life Sciences and gave the stock a “buy” rating in a research report on Tuesday, September 29th. Wall Street Zen lowered shares of Achieve Life Sciences from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 15th. Finally, Raymond James Financial reissued a “strong-buy” rating and set a $18.00 price target on shares of Achieve Life Sciences in a research report on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $15.50.

About Achieve Life Sciences

Achieve Life Sciences, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cytisinicline, a therapy designed to help adults quit smoking and overcome nicotine addiction. Cytisinicline is an oral, plant-based small molecule that partially activates nicotinic acetylcholine receptors, with the goal of reducing nicotine cravings and withdrawal symptoms.

The company has evaluated cytisinicline in clinical studies involving adults who smoke cigarettes, including trials assessing smoking cessation and cessation of electronic cigarette use.